Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Pirlich

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|January 8, 2025
Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center's experienceGunnar Wichmann, Theresa Wald, Veit Zebralla, et al.
Laryngo- Rhino- Otologie|September 29, 2022
[Current Therapy Standards for Soft Tissue Sarcomas in the Head and Neck Area - Part 2]Andreas Dietz, Bernd Lethaus, Markus Pirlich, et al.
Laryngo- Rhino- Otologie|August 30, 2022
[Current Therapy Standards for Soft Tissue Sarcomas in the Head and Neck Area - Part 1]Andreas Dietz, Bernd Lethaus, Markus Pirlich, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|August 2, 2022
Diameter of the Cochlear Nerve Canal predicts Cochlear Nerve Deficiency in Children with Sensorineural Hearing LossMartin Sorge, Ina Sorge, Markus Pirlich, et al.
Biomedicines|September 28, 2024
Outcome Disparities in Patients with Early-Stage Laryngeal Cancer Depending on Localization, Tobacco Consumption, and Treatment ModalityTheresa Wald, Tim-Jonathan Koppe, Markus Pirlich, et al.
Laryngo- Rhino- Otologie|April 4, 2022
[Presentation and evaluation of the haptic-visual ear surgery training system "HaptiVisT"]Martin Sorge, Thomas Eixelberger, Andreas Dietz, et al.
Cancers|August 7, 2021
Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC)Julia Siemert, Theresa Wald, Marlen Kolb, et al.
Laryngo- Rhino- Otologie|May 16, 2022
[Pembrolizumab and Cetuximab as therapeutic options for ACC in head and neck]Ioannis Michaelides, Sandra Fest, Michael Berszin, et al.
Frontiers in Immunology|October 18, 2023
Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcomeLouisa Röhl, Jana Wellhausen, Michael Berszin, et al.
Frontiers in Immunology|January 30, 2025
Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC <i>ex vivo</i> by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survivalJana Wellhausen, Louisa Röhl, Michael Berszin, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|January 8, 2025
Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center's experienceGunnar Wichmann, Theresa Wald, Veit Zebralla, et al.
Laryngo- Rhino- Otologie|September 29, 2022
[Current Therapy Standards for Soft Tissue Sarcomas in the Head and Neck Area - Part 2]Andreas Dietz, Bernd Lethaus, Markus Pirlich, et al.
Laryngo- Rhino- Otologie|August 30, 2022
[Current Therapy Standards for Soft Tissue Sarcomas in the Head and Neck Area - Part 1]Andreas Dietz, Bernd Lethaus, Markus Pirlich, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|August 2, 2022
Diameter of the Cochlear Nerve Canal predicts Cochlear Nerve Deficiency in Children with Sensorineural Hearing LossMartin Sorge, Ina Sorge, Markus Pirlich, et al.
Biomedicines|September 28, 2024
Outcome Disparities in Patients with Early-Stage Laryngeal Cancer Depending on Localization, Tobacco Consumption, and Treatment ModalityTheresa Wald, Tim-Jonathan Koppe, Markus Pirlich, et al.
Laryngo- Rhino- Otologie|April 4, 2022
[Presentation and evaluation of the haptic-visual ear surgery training system "HaptiVisT"]Martin Sorge, Thomas Eixelberger, Andreas Dietz, et al.
Cancers|August 7, 2021
Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC)Julia Siemert, Theresa Wald, Marlen Kolb, et al.
Laryngo- Rhino- Otologie|May 16, 2022
[Pembrolizumab and Cetuximab as therapeutic options for ACC in head and neck]Ioannis Michaelides, Sandra Fest, Michael Berszin, et al.
Frontiers in Immunology|October 18, 2023
Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcomeLouisa Röhl, Jana Wellhausen, Michael Berszin, et al.
Frontiers in Immunology|January 30, 2025
Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC <i>ex vivo</i> by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survivalJana Wellhausen, Louisa Röhl, Michael Berszin, et al.
Pageof 4